AXSM News and Press, Axsome Therapeutics Inc. From 03/19/24

2024-03-19 14:16:52 ET More on Axsome Therapeutics Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript Axsome: Show Me Another Company With Such A Stack Of Catalysts ...

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial...

2024-03-10 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Off...

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Offi...

2024-02-26 08:50:00 ET The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next de...

2024-02-21 16:20:58 ET Summary Auvelity shows growth with $130.1 million annual sales, impressive in a crowded depression treatment market. Axsome's Q4 reveals surging revenues but widened losses due to high R&D and SG&A expenses. The cash position is strong, however, ...

2024-02-20 18:47:07 ET Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Conference Call February 20, 2024 08:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer ...

2024-02-20 18:00:16 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q4 2023 Earnings Call Feb 20, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Tran...

2024-02-20 07:10:40 ET More on Axsome Therapeutics Axsome: Show Me Another Company With Such A Stack Of Catalysts Axsome Therapeutics: Positive Q3, We Like The Launch Success Story Axsome Therapeutics Q4 2023 Earnings Preview UBS starts Axsome at buy, sees Au...